Safety and immunogenicity of palivizumab (Synagis) administered for two seasons

Donald Null, Bernard Pollara, Penelope H. Dennehy, Jean Steichen, Pablo J. Sanchez, Laurence B. Givner, David Carlin, Bernard Landry, Franklin H. Top, Edward Connor

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

To evaluate the safety and inimunogenicity of palivizumab, 55 children who received palivizumab in the IMpact-RSV trial received 5 monthly doses of 15 mg/kg palivizumab (Synagis) during the subsequent year. The single child with an antipalivizumab titer of >1/40 had no associated serious adverse events and had expected serum palivizumab trough concentrations. Second year palivizumab prophylaxis was safe and well-tolerated.

Original languageEnglish (US)
Pages (from-to)1021-1023
Number of pages3
JournalPediatric Infectious Disease Journal
Volume24
Issue number11
DOIs
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Safety
Palivizumab
Serum

Keywords

  • Monoclonal antibody
  • Palivizumab
  • Respiratory syncytial virus
  • Synagis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Null, D., Pollara, B., Dennehy, P. H., Steichen, J., Sanchez, P. J., Givner, L. B., ... Connor, E. (2005). Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatric Infectious Disease Journal, 24(11), 1021-1023. https://doi.org/10.1097/01.inf.0000183938.33484.bd

Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. / Null, Donald; Pollara, Bernard; Dennehy, Penelope H.; Steichen, Jean; Sanchez, Pablo J.; Givner, Laurence B.; Carlin, David; Landry, Bernard; Top, Franklin H.; Connor, Edward.

In: Pediatric Infectious Disease Journal, Vol. 24, No. 11, 01.01.2005, p. 1021-1023.

Research output: Contribution to journalArticle

Null, D, Pollara, B, Dennehy, PH, Steichen, J, Sanchez, PJ, Givner, LB, Carlin, D, Landry, B, Top, FH & Connor, E 2005, 'Safety and immunogenicity of palivizumab (Synagis) administered for two seasons', Pediatric Infectious Disease Journal, vol. 24, no. 11, pp. 1021-1023. https://doi.org/10.1097/01.inf.0000183938.33484.bd
Null, Donald ; Pollara, Bernard ; Dennehy, Penelope H. ; Steichen, Jean ; Sanchez, Pablo J. ; Givner, Laurence B. ; Carlin, David ; Landry, Bernard ; Top, Franklin H. ; Connor, Edward. / Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. In: Pediatric Infectious Disease Journal. 2005 ; Vol. 24, No. 11. pp. 1021-1023.
@article{edd505ecea3f49988360c6574346bb2d,
title = "Safety and immunogenicity of palivizumab (Synagis) administered for two seasons",
abstract = "To evaluate the safety and inimunogenicity of palivizumab, 55 children who received palivizumab in the IMpact-RSV trial received 5 monthly doses of 15 mg/kg palivizumab (Synagis) during the subsequent year. The single child with an antipalivizumab titer of >1/40 had no associated serious adverse events and had expected serum palivizumab trough concentrations. Second year palivizumab prophylaxis was safe and well-tolerated.",
keywords = "Monoclonal antibody, Palivizumab, Respiratory syncytial virus, Synagis",
author = "Donald Null and Bernard Pollara and Dennehy, {Penelope H.} and Jean Steichen and Sanchez, {Pablo J.} and Givner, {Laurence B.} and David Carlin and Bernard Landry and Top, {Franklin H.} and Edward Connor",
year = "2005",
month = "1",
day = "1",
doi = "10.1097/01.inf.0000183938.33484.bd",
language = "English (US)",
volume = "24",
pages = "1021--1023",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Safety and immunogenicity of palivizumab (Synagis) administered for two seasons

AU - Null, Donald

AU - Pollara, Bernard

AU - Dennehy, Penelope H.

AU - Steichen, Jean

AU - Sanchez, Pablo J.

AU - Givner, Laurence B.

AU - Carlin, David

AU - Landry, Bernard

AU - Top, Franklin H.

AU - Connor, Edward

PY - 2005/1/1

Y1 - 2005/1/1

N2 - To evaluate the safety and inimunogenicity of palivizumab, 55 children who received palivizumab in the IMpact-RSV trial received 5 monthly doses of 15 mg/kg palivizumab (Synagis) during the subsequent year. The single child with an antipalivizumab titer of >1/40 had no associated serious adverse events and had expected serum palivizumab trough concentrations. Second year palivizumab prophylaxis was safe and well-tolerated.

AB - To evaluate the safety and inimunogenicity of palivizumab, 55 children who received palivizumab in the IMpact-RSV trial received 5 monthly doses of 15 mg/kg palivizumab (Synagis) during the subsequent year. The single child with an antipalivizumab titer of >1/40 had no associated serious adverse events and had expected serum palivizumab trough concentrations. Second year palivizumab prophylaxis was safe and well-tolerated.

KW - Monoclonal antibody

KW - Palivizumab

KW - Respiratory syncytial virus

KW - Synagis

UR - http://www.scopus.com/inward/record.url?scp=28044466643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28044466643&partnerID=8YFLogxK

U2 - 10.1097/01.inf.0000183938.33484.bd

DO - 10.1097/01.inf.0000183938.33484.bd

M3 - Article

C2 - 16282947

AN - SCOPUS:28044466643

VL - 24

SP - 1021

EP - 1023

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 11

ER -